Selection of currently ongoing clinical pharmaceutical trials at the NCRC

Multiple Sclerosis Studies / MOGAD:

Titel

   NCT-Number

 Recruitment status
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)

   NCT04411641 activ
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)

   NCT04458051 activ
WN43194 Satralizumab phase iii (Meteoroid)

    in preparation
Study MOG001 (Parexel 247511) phase iii (CosMOG)
    in preparation

 

Myasthenia gravis studies:

Titel

   NCT-Number

 Recruitment status
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis 

   NCT03920293 activ
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

   NCT04818671 activ
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis

   NCT04951622 in preparation
A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis   NCT04980495 in preparation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

   NCT05218096 in preparation

 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) studies:

Titel

   NCT-Number

   Recruitment status
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)

   NCT04281472   activ
Gamunex® 10% Use in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) in clinical Routine:
 Observational study to assess Individualized Treatment Decisions (I-GUIDE)		   Sponsor-Reg.GPN-001   activ